Works by Helong Zhang

Results: 75
    1
    2

    Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double‐Blinded, Placebo‐Controlled, Randomized Phase III Trial (ALTER0703).

    Published in:
    Oncologist, 2021, v. 26, n. 10, p. e1693, doi. 10.1002/onco.13857
    By:
    • Chi, Yihebali;
    • Shu, Yongqian;
    • Ba, Yi;
    • Bai, Yuxian;
    • Qin, Baoli;
    • Wang, Xiuwen;
    • Xiong, Jianping;
    • Xu, Nong;
    • Zhang, Helong;
    • Zhou, Jianfeng;
    • Xu, Jianming;
    • Cheng, Ying;
    • Feng, Jifeng;
    • Hu, Chunhong;
    • Chen, Yigui;
    • Chen, Zhendong;
    • Wang, Jufeng;
    • Dang, Chengxue;
    • Wang, Jianhong;
    • Wan, Yiye
    Publication type:
    Article
    3
    4

    Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).

    Published in:
    BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02738-5
    By:
    • Shi, Yuankai;
    • Chen, Jianhua;
    • Zhang, Helong;
    • Zhang, Zhihong;
    • Zhang, Yiping;
    • Wang, Zhehai;
    • Zhang, Shucai;
    • Zhao, Jian;
    • Liu, Chunling;
    • Wang, Xiuwen;
    • Zhao, Yanqiu;
    • Hu, Changlu;
    • Yang, Lei;
    • Hao, Xuezhi;
    • Wang, Lin;
    • Liu, Yunpeng;
    • Yu, Yan;
    • Zhao, Jun;
    • Wang, Mengzhao;
    • Zhang, Liangming
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33

    Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 22, p. 20847, doi. 10.1002/cam4.6664
    By:
    • Chen, Likun;
    • Rangel, Jose David Gomez;
    • Cil, Timucin;
    • Li, Xingya;
    • Cicin, Irfan;
    • Shen, Yihong;
    • Liu, Zhihua;
    • Ozyilkan, Ozgur;
    • Igor, Bondarenko;
    • Chen, Jun;
    • Oleksandr, Kostiuk;
    • Chen, Zhendong;
    • Zhang, Helong;
    • Fu, Ziyi;
    • Dong, Qingfeng;
    • Song, Shuqiang;
    • Yu, Jin‐Chen;
    • Zhang, Li;
    • Hryhoriy, Adamchuk;
    • Karaoglu, Aziz
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42

    First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 4, p. 695, doi. 10.1007/s10147-022-02120-0
    By:
    • John, Thomas;
    • Sakai, Hiroshi;
    • Ikeda, Satoshi;
    • Cheng, Ying;
    • Kasahara, Kazuo;
    • Sato, Yuki;
    • Nakahara, Yoshiro;
    • Takeda, Masayuki;
    • Kaneda, Hiroyasu;
    • Zhang, Helong;
    • Maemondo, Makoto;
    • Minato, Koichi;
    • Hisada, Takeshi;
    • Misumi, Yuki;
    • Satouchi, Miyako;
    • Hotta, Katsuyuki;
    • Li, Ang;
    • Oukessou, Abderrahim;
    • Lu, Shun
    Publication type:
    Article
    43

    Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.

    Published in:
    Signal Transduction & Targeted Therapy, 2021, v. 6, n. 1, p. 1, doi. 10.1038/s41392-021-00751-9
    By:
    • Jiang, Tao;
    • Wang, Pingyang;
    • Zhang, Jie;
    • Zhao, Yanqiu;
    • Zhou, Jianying;
    • Fan, Yun;
    • Shu, Yongqian;
    • Liu, Xiaoqing;
    • Zhang, Helong;
    • He, Jianxing;
    • Gao, Guanghui;
    • Mu, Xiaoqian;
    • Bao, Zhang;
    • Xu, Yanjun;
    • Guo, Renhua;
    • Wang, Hong;
    • Deng, Lin;
    • Ma, Ningqiang;
    • Zhang, Yalei;
    • Feng, Hui
    Publication type:
    Article
    44

    Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.

    Published in:
    Signal Transduction & Targeted Therapy, 2021, v. 6, n. 1, p. 1, doi. 10.1038/s41392-021-00751-9
    By:
    • Jiang, Tao;
    • Wang, Pingyang;
    • Zhang, Jie;
    • Zhao, Yanqiu;
    • Zhou, Jianying;
    • Fan, Yun;
    • Shu, Yongqian;
    • Liu, Xiaoqing;
    • Zhang, Helong;
    • He, Jianxing;
    • Gao, Guanghui;
    • Mu, Xiaoqian;
    • Bao, Zhang;
    • Xu, Yanjun;
    • Guo, Renhua;
    • Wang, Hong;
    • Deng, Lin;
    • Ma, Ningqiang;
    • Zhang, Yalei;
    • Feng, Hui
    Publication type:
    Article
    45

    Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.

    Published in:
    Signal Transduction & Targeted Therapy, 2021, v. 6, n. 1, p. 1, doi. 10.1038/s41392-021-00751-9
    By:
    • Jiang, Tao;
    • Wang, Pingyang;
    • Zhang, Jie;
    • Zhao, Yanqiu;
    • Zhou, Jianying;
    • Fan, Yun;
    • Shu, Yongqian;
    • Liu, Xiaoqing;
    • Zhang, Helong;
    • He, Jianxing;
    • Gao, Guanghui;
    • Mu, Xiaoqian;
    • Bao, Zhang;
    • Xu, Yanjun;
    • Guo, Renhua;
    • Wang, Hong;
    • Deng, Lin;
    • Ma, Ningqiang;
    • Zhang, Yalei;
    • Feng, Hui
    Publication type:
    Article
    46
    47
    48
    49
    50